

Third-Quarter

# 2024 Financial Results



Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world



Demonstrated strong progress across the business



Achieved significant regulatory and clinical milestones



Expanded and diversified pipeline



“Our third-quarter results were strong, as we continue to make progress heading into 2025 and beyond. Our pipeline is advancing and expanding, demonstrating our success in creating a sustainable innovation engine, and positioning MSD with a more diversified portfolio to drive growth. I continue to remain confident in the strength of our business and our ability to execute, and I want to thank our colleagues across the globe for their focus and commitment as we work to create lasting value for patients, shareholders and all our stakeholders.”

Rob Davis  
Chairman and Chief Executive Officer, MSD

WORLDWIDE SALES

GAAP EPS<sup>1</sup>

NON-GAAP EPS<sup>1,2</sup>

Q3 performance reflects continued growth

\$16.7B

\$1.24

\$1.57

Updated ranges for 2024 financial outlook

\$63.6B  
to  
\$64.1B

\$7.72  
to  
\$7.77

**KEYTRUDA**  
(pembrolizumab) injection 100 mg

**WINREVAIR**  
(sotatercept) injection 50 mg, 60 mg

**MSD**  
Animal Health

Sales

\$7.4B  
17% Growth

\$149M

\$1.5B  
6% Growth



# Q3

2024  
Financial Results

<sup>1</sup> GAAP and non-GAAP EPS in the third quarter of 2024 include a net charge of \$0.79 per share in the aggregate related to certain business development transactions.

<sup>2</sup> A reconciliation of GAAP to non-GAAP EPS can be found in the company's earnings release.